tailieunhanh - Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). | Safety and antitumor activity of the anti PD-1 antibody pembrolizumab in patients with advanced PD-L1 positive papillary or follicular thyroid cancer

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN